

S2 Table. Univariate and multivariate analysis of progression-free survival for second-line chemotherapy

	Univariate analysis		Multivariate analysis	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Sex				
Male	Reference		Reference	
Female	1.16 (0.79-1.70)	0.45	1.12 (0.76-1.64)	0.57
Initial disease status				
Recurred	Reference		-	-
Metastatic	0.87 (0.57-1.32)	0.51	-	-
Age (yr)				
≤ 60	Reference		Reference	
> 60	1.12 (0.76-1.65)	0.57	1.11 (0.75-1.64)	0.60
ECOG performance status				
0	Reference		Reference	
1-2	0.75 (0.50-1.10)	0.14	0.77 (0.52-1.14)	0.20
CA19-9				
Normal	Reference		-	-
Elevated	1.04 (0.60-1.79)	0.89	-	-
Albumin				
Normal	Reference		-	-
Decreased	1.05 (0.72-1.53)	0.81	-	-
NLR				
≤ 2.2	Reference		-	-
> 2.2	1.12 (0.77-1.64)	0.55	-	-
PLR				
≤ 154.4	Reference		-	-
> 154.4	1.08 (0.74-1.58)	0.69	-	-
Number of metastatic sites				
0-1	Reference		-	-
≥ 2	1.06 (0.72-1.55)	0.77	-	-
Presence of liver metastasis				
No	Reference		Reference	
Yes	1.51 (1.03-2.23)	0.04	1.51 (1.02-2.24)	0.04
Presence of lung metastasis				
No	Reference		-	-
Yes	0.86 (0.56-1.32)	0.86	-	-
Presence of bone metastasis				
No	Reference		-	-
Yes	0.90 (0.42-1.96)	0.90	-	-
Presence of peritoneal metastasis				
No	Reference		-	-
Yes	0.84 (0.57-1.24)	0.38	-	-
Presence of lymph nodes metastasis				
No	Reference		-	-
Yes	0.81 (0.54-1.22)	0.32	-	-
1L-TTP (mo)				
≤ 6.4	1.18 (0.81-1.73)	0.39	-	-
> 6.4	Reference		-	-
Best response for first-line nab-P+GEM				
CR/PR/SD	Reference		-	-

PD	0.75 (0.45-1.26)	0.28	-	-
Second-line regimen				
Fluoropyrimidine monotherapy	Reference		-	-
Fluoropyrimidine-oxaliplatin doublets	0.83 (0.54-1.28)	0.40	-	-

HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; CA19-9, carbohydrate antigen 19-9; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; 1L, first line; TTP time to progression; *nab*-P+GEM, *nab*-paclitaxel plus gemcitabine; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.